Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum

References

• Vacca JB, Knight WA Jr, Broun GO Sr. Clinical observations regarding xanthelasma. Ann Intern Med. 1959;51:1019–1031.
   PubMed Web of Science ®Google Scholar
• Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma Palpebrarum-clinical and biochemical profile in a tertiary care hospital of Delhi. Indian J Clin Biochem. 2007;22(2):151–153. doi:10.1007/BF02913335
   PubMedGoogle Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–714. doi:10.1016/0002-9343(77)90874-9
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M, Ako J, Arai H, et al. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: results of the EXPLORE-J study. Atherosclerosis. 2018;277:362–368. doi:10.1016/j.atherosclerosis.2018.06.856
   PubMed Web of Science ®Google Scholar
• Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV. Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J. 2012;88(1038):198–204. doi:10.1136/postgradmedj-2011-130443
   PubMed Web of Science ®Google Scholar
• Chang HC, Sung CW, Lin MH. Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):596–605. doi:10.1016/j.jaad.2019.08.082
   PubMed Web of Science ®Google Scholar
• Bergman R. Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol. 1998;37(5):343–345. doi:10.1046/j.1365-4362.1998.00362.x
   PubMed Web of Science ®Google Scholar
• Watanabe A, Yoshimura A, Wakasugi T, et al. Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis. 1981;38(3–4):283–290. doi:10.1016/0021-9150(81)90044-7
   PubMed Web of Science ®Google Scholar
• Laftah Z, Al-Niaimi F. Xanthelasma: an update on treatment modalities. J Cutan Aesthet Surg. 2018;11(1):1–6. doi:10.4103/JCAS.JCAS_56_17
   PubMedGoogle Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137–141. doi:10.1016/j.soard.2014.06.015
   PubMed Web of Science ®Google Scholar
• Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113–119. doi:10.1111/j.1478-3231.2008.01718.x
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508. doi:10.1016/j.dld.2009.08.002
   PubMedGoogle Scholar
• Wang J, Xu C, Xun Y, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015;16(5):16494. doi:10.1038/srep16494
   Google Scholar
• Ahrens M, Ammerpohl O, von Schönfels W, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18(2):296–302. doi:10.1016/j.cmet.2013.07.004
   PubMed Web of Science ®Google Scholar
• Horvath S, Erhart W, Brosch M, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A. 2014;111(43):15538–15543. doi:10.1073/pnas.1412759111
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–D855. doi:10.1093/nar/gkz1021
   PubMed Web of Science ®Google Scholar
• Bastida JM, Benito R, Janusz K, et al. Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia. J Thromb Haemost. 2017;15(9):1859–1866. doi:10.1111/jth.13777
   PubMed Web of Science ®Google Scholar
• Huang D, Zhou Q, Chao YQ, Zou CC. Clinical features and genetic analysis of childhood sitosterolemia: two case reports and literature review. Medicine (Baltimore). 2019;98(15):e15013. doi:10.1097/MD.0000000000015013
   PubMed Web of Science ®Google Scholar
• Tada H, Kawashiri MA, Ohtani R, et al. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis. 2011;219(2):663–666. doi:10.1016/j.atherosclerosis.2011.08.004
   PubMed Web of Science ®Google Scholar
• Saavedra YG, Dufour R, Davignon J, Baass A. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Arterioscler Thromb Vasc Biol. 2014;34(12):2700–2705. doi:10.1161/ATVBAHA.114.304406
   PubMed Web of Science ®Google Scholar
• Oosterveer DM, Versmissen J, Yazdanpanah M, et al. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia. Atherosclerosis. 2009;206(1):223–227. doi:10.1016/j.atherosclerosis.2009.02.019
   PubMed Web of Science ®Google Scholar
• Bardawil T, Rebeiz A, Chaabouni M, et al. Mutations in the ABCG8 gene are associated with sitosterolaemia in the homozygous form and xanthelasmas in the heterozygous form. Eur J Dermatol. 2017;27(5):519–523. doi:10.1684/ejd.2017.3087
   PubMed Web of Science ®Google Scholar
• Hu M, Yuen YP, Kwok JS, Griffith JF, Tomlinson B. Potential effects of NPC1L1 polymorphisms in protecting against clinical disease in a chinese family with sitosterolaemia. J Atheroscler Thromb. 2014;21(9):989–995. doi:10.5551/jat.24679
   PubMed Web of Science ®Google Scholar
• Mabuchi H. Half a century tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb. 2017;24(3):189–207. doi:10.5551/jat.RV16008
   PubMed Web of Science ®Google Scholar
• Gaspar IM, Gaspar A. Variable expression and penetrance in Portuguese families with familial hypercholesterolemia with mild phenotype. Atheroscler Suppl. 2019;36:28–30. doi:10.1016/j.atherosclerosissup.2019.01.006
   PubMed Web of Science ®Google Scholar
• Donato LJ, Saenger AK, Train LJ, et al. Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis. J Clin Apher. 2014;29(5):256–265. doi:10.1002/jca.21317
   PubMed Web of Science ®Google Scholar
• Tursen U, Eskandari G, Kaya TI, Tamer L, Ikizoglu G, Atik U. Apolipoprotein E polymorphism and lipoprotein compositions in normolipidaemic xanthelasma patients. J Eur Acad Dermatol Venereol. 2006;20(3):260–263. doi:10.1111/j.1468-3083.2006.01418.x
   PubMed Web of Science ®Google Scholar
• Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37:W305–11. doi:10.1093/nar/gkp427
   PubMed Web of Science ®Google Scholar
• Su HC, Wu SC, Yen LC, et al. Gene expression profiling identifies the role of Zac1 in cervical cancer metastasis. Sci Rep. 2020;10(1):11837. doi:10.1038/s41598-020-68835-0
   PubMed Web of Science ®Google Scholar
• Al Aboud AM, Al Aboud DM. Xanthelasma Palpebrarum. Updated 2020 Aug 10. In: StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing; 2021. Available from https://www.ncbi.nlm.nih.gov/books/NBK531501/. Accessed April 30, 2021.
   Google Scholar
• Nair PA, Patel CR, Ganjiwale JD, Diwan NG, Jivani NB. Xanthelasma palpebrarum with arcus cornea: a clinical and biochemical Study. Indian J Dermatol. 2016;61(3):295–300. doi:10.4103/0019-5154.182426
   PubMed Web of Science ®Google Scholar
• Dey A, Aggarwal R, Dwivedi S. Cardiovascular profile of xanthelasma palpebrarum. Biomed Res Int. 2013;2013:932863. doi:10.1155/2013/932863
   PubMed Web of Science ®Google Scholar
• Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280–287. doi:10.1001/jamacardio.2018.0022
   PubMed Web of Science ®Google Scholar
• Sugino I, Kuboki K, Matsumoto T, Murakami E, Nishimura C, Yoshino G. Influence of fatty liver on plasma small, dense LDL- cholesterol in subjects with and without metabolic syndrome. J Atheroscler Thromb. 2011;18(1):1–7. doi:10.5551/jat.5447
   PubMed Web of Science ®Google Scholar
• Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006;29(8):1845–1850. doi:10.2337/dc06-0455
   PubMed Web of Science ®Google Scholar
• Ozdol S, Sahin S, Tokgozoglu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein. Int J Dermatol. 2008;47(8):785–789. doi:10.1111/j.1365-4632.2008.03690.x
   PubMed Web of Science ®Google Scholar
• Noel B. Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol. 2007;21(9):1244–1248. doi:10.1111/j.1468-3083.2007.02252.x
   PubMed Web of Science ®Google Scholar